Chinese Stroke Drug Doubles Treatment Window to 2 Days

When someone has a stroke, a clot blocks blood flow to the brain, and brain cells begin dying within minutes. That is why doctors call strokes a race against the clock: clot-busting drugs and surgery normally must be given within six hours, or the damage becomes permanent — affecting speech, movement and sometimes life itself. Miss that window, and treatment options mostly dry up.

A new Chinese-developed drug, Loberamisal, appears to break that deadline. In a large trial published in the Journal of the American Medical Association, nearly 1,000 patients at 32 hospitals received the drug intravenously up to two days after their stroke. Seventy per cent of them regained complete functional independence — meaning they could handle daily life on their own — compared with standard care alone. That is a 13 percentage point improvement, a meaningful jump in medicine where gains are usually measured in single digits.

The idea behind the drug is to protect brain cells from the cascade of damage that continues after the initial blockage, effectively buying the brain time to heal. For families, this changes everything about how quickly they need to act and how much hope doctors can offer. Instead of a frantic six-hour scramble, patients arriving at hospital late may still have a real chance at recovery.

There are caveats. The results come from one trial, and the drug still needs regulatory approval before hospitals can use it. Cost, availability and how well it works alongside existing treatments are open questions. Even so, this is one of the biggest shifts in stroke care in decades — and a reminder that the clock may soon stop deciding who recovers and who does not.